Impel Pharmaceuticals Inc. (NASDAQ:IMPL) Q2 2022 Earnings Conference Call August 15, 2022 8:30 AM ET

Company Participants

John Leaman - Chief Financial & Business Officer

Adrian Adams - Chairman & CEO

Leonard S. Paolillo - Chief Commercial Officer

Conference Call Participants

Ken Cacciatore - Cowen

Laura Chico - Wedbush

Eddie Hickman - Guggenheim Securities

Operator

Good morning, ladies and gentlemen and welcome to Impel Pharmaceuticals’ Second Quarter 2022 Earnings and Business Update Conference Call. At this time, all participants are in a listen-only mode. Later on this call the question-and-answer session will be conducted and instructions on how to participate will be given at that time. As a reminder, today's conference call is being recorded. Now I would like to turn the conference over to Impel’s Chief Financial and Business Officer, Dr. John Leaman, you may begin.

John Leaman

Thank you, Kevin and good morning, everyone. We are delighted that you could join us today for Impel Pharmaceuticals’ quarterly earnings conference call to review our second quarter 2022 commercial and financial results, as well as providing general business update. Joining me from Impel this morning is Adrian Adams, Impel’s Chairman of the Board and Chief Executive Officer; and Len Paolillo, our Chief Commercial Officer.

Before we begin, I'd like to remind everyone that we have a slide presentation to accompany our conference call this morning, which can be viewed at our website at www.impelpharma.com. If you are listening to this call on your telephone, you may access a synchronized slide deck on our website, by choosing the link on our webcast page that says, click here to listen. Please advance to Slide 2, forward-looking statements. I would like to remind you that during the call, the company will be making forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ from the results discussed in the forward-looking statements. With that, I will turn the call over to Adrian Adams. Adrian?

Adrian Adams

Thank you, John. Good morning, everyone and thank you all for joining us. I am both pleased and excited to update you on the commercial and corporate progress we've made since our first quarter earnings call in May of this year. The agenda for today's call can be seen on our next slide, Slide Number 3. During this call, we will provide a prescription performance update for Trudhesa in addition to covering ongoing positive market access, reimbursement, and source of business momentum in the second quarter and year-to-date 2022. We will then briefly review our second quarter and year-to-date financial performance and provide a status update on the market and clinical development opportunity with INP105 for the treatment of autism before presenting an overall summary and outlook and then answering some questions from you all.